Statements concerning authors' potential conflicts of interest have become standard and, in fact, required features in most medical journals. A few years ago, Aaron Kesselheim and colleagues 11 thought it would be interesting to investigate how such disclosures affect readers' responses to the associated articles. Their study, published in the 2012 New England Journal of Medicine (NEJM), stimulated an accompanying editorial and a spirited flurry of correspondence.
For this exercise, the authors fabricated clinical trial reports on fictional new drugs for the treatment of hyperlipidemia, diabetes, and angina pectoris. In light of evidence that internists frequently read only the abstracts of journal articles (note to self: future editorial topic), they crafted a set of 3 different abstracts reporting fictitious trials of each of the 3 drugs. One abstract in each set described a study of high methodological rigor, while the other 2 were considered methodologically intermediate and low according to published standards. Finally, the investigators added another layer of complexity by varying the hypothetical funding status of each abstract: some were designated as funded by the US National Institutes of Health (NIH), some by a large pharmaceutical company with which the lead author reported a financial relationship, and in some no source of funding was identified. For those keeping score at home, this resulted in 27 different permutations.
Each of the 269 internists who agreed to participate in the study received 3 abstracts, 1 for each drug. They were told to assume that the drugs were recently approved by the US Food and Drug Administration, that the abstracts were from a ''high impact'' journal, and that the authors were on the faculty of an established American university. The methodological rigor and funding information of the abstracts were randomly varied to produce a balanced distribution of the various permutations. Physicians were asked to rate on a 7-point Likert scale the rigor of the trial, their confidence in the investigators' conclusions, and their likelihood of prescribing the new drug.
The results of the study may or may not surprise you. To the credit of the participants, they were usually able to rate the rigor of the trial designs correctly, and their likelihood of prescribing the drugs increased according to the rigor of the trial. If industry funding was declared in the abstract, however, the internists downgraded the rigor of the trial, were less confident in its conclusions, and stated that they were less likely to prescribe the drug than when the trial was NIH funded or no funding source was identified. In fact, they declared themselves half as likely to prescribe a drug tested in an industry-sponsored trial than if the trial was funded by the NIH.
In their discussion, Kesselheim and colleagues 11 praised the ability of the participants to rate the methodological rigor of the studies correctly, but they expressed their concern that the internists tended to downgrade the credibility of an industry-funded study that was otherwise identical to one financed by the NIH. Jeffrey Drazen, the editor of the NEJM, echoed this sentiment in an accompanying editorial, urging readers to ''believe the data'' and judge a study by the details of its methodology, not its source of funding. 7 Some of the ensuing correspondents supported this sentiment, while others decried it, recalling prior scandals and citing evidence that industry-sponsored research was more likely to report favorably on a new drug than independently funded work. 10, 12 One group of letter writers questioned the real-world relevance of the Kesselheim et al study. 9 They pointed out that, in reality, commercial funding of research did not seem to affect physician behavior, because the drugs most frequently prescribed at the time were all approved after industrysponsored trials.
Other investigations into the effect of conflict-of-interest declarations have varied in their conclusions. Comparable studies among readers of The BMJ, another prominent medical journal, had similar findings 5 but reported that readers discounted the findings of a paper more when an author declared a financial interest than if the study was merely funded by a grant from industry. 17 On the other hand, while a group of obstetrician-gynecologists said that they take the funding source into consideration when evaluating a research study, this did not affect their likelihood of prescribing an investigated drug. 18 Similarly, most reviewers for the Annals of Emergency Medicine stated that they would read a paper more carefully if they knew that the authors had a commercial affiliation, but that this would not influence their publication recommendation. 13 Finally, a 2014 study among French general practitioners found no significant difference in their evaluation of abstracts of a randomized trial based on funding source or author conflict of interest. 3 It is easy to understand why declarations of funding source and relevant financial relationships have become a required feature of medical presentations and publications. Although a few high-profile scandals are often cited in which pharmaceutical firms have been accused of suppressing unfavorable effects of their products, 8, 19 a greater concern is the possibility that financial considerations may bias the design or reporting of clinical trials. Supporting such concerns are reports such as the 2010 examination by Bourgeois et al 2 of safety and efficacy trials registered in ClinicalTrials.gov of 5 commonly prescribed classes of drugs. The finding that positive outcomes were reported in 85.4% of industry-funded studies-compared with 50% of government-funded trials and 61.2% of trials supported solely by nonprofit or nonfederal organizations-might raise the suspicion that industry funding had exerted an inappropriate influence on the conduct or reporting of this research.
However, not all potential explanations for these findings suggest nefarious corporate behavior. The same study also found that industry-funded trials were more likely to be phase 3 or 4, use an active comparator, be multicenter, and enroll more participants than the other studies. It stands to reason that companies are more likely to proceed with advanced phases of testing with drugs that show promise in the early stages of evaluation, whereas governments and foundations may be more apt to support evaluation of investigational compounds whose efficacy is less certain. Additionally, larger trials have greater statistical power and are thus more likely to demonstrate a significant difference between alternatives.
However, there are other, less benign factors that may have contributed to the noted difference in study outcome according to funding source. One of these might be inferred from the additional finding of Bourgeois et al 2 that only 32.4% of industry-funded registered trials were published within 2 years of completion, compared with 56.2% of trials funded by nonprofit or nonfederal sources without any industry contributions. While it is understandable that a company operating in a competitive environment might not be in a rush to identify unsuccessful avenues of research and thus possibly help focus the drug development efforts of its competitors, the conservation of resources that might result from doing so would be more beneficial for society at large.
Bourgeois et al 2 also point out that decisions made in the planning phases of a study can enhance the possibility of a positive outcome. The precise study questions selected, as well as the choices of comparator treatment, drug doses, clinical endpoints, and duration of follow-up, may all influence the ultimate result, often in predictable ways. 1, 2, 15 After the study is completed and a report is being prepared for publication, selective emphasis on certain outcome parameters and a well-crafted discussion can also maximize its positive impact. Some even argue that requiring the inclusion of a conflict-of-interest declaration may have the unintended effect of increasing such author behavior by moral licensing, the ethical term for an often unconscious feeling on the part of an author that biased advice is justifiable because the advisee has been forewarned. 4, 14, 20 It has often been pointed out that relationships with industry are far from the only factors that may lead to a biased presentation of a study; they are merely the most easily identifiable. 7, 16, 20 Indeed, authors receiving funding from government agencies or private foundations may feel pressure to produce ''positive'' results to justify continued financial support. Personal relationships, entrenched opinions, and the simple desire to maximize the importance of one's research are potentially conflicting interests that should be considered when evaluating any scientific publication. As the editor of the Journal of Psychiatry and Neuroscience stated, ''the idea that scientists are objective seekers of truth is a pleasing fiction, but counterproductive in so far as it can lessen vigilance against bias.'' 20(p412) Industry continues to be the dominant source of funding for pharmaceutical and other biomedical research. 6 Although orthopaedic sports medicine research is more likely to involve devices than drugs, the issue of conflict of interest remains pertinent to our field. At The American Journal of Sports Medicine, we agree that commercial relationships should be kept in mind when assessing scientific studies, but we feel that all papers should be scrutinized for possible bias in the presentation of the results. Research should ultimately be judged by its content, not by its funding. Reflecting this attitude, author declarations are not shared with reviewers, a policy designed to encourage them to focus on the content of each paper and call attention to any areas of possible bias, commercial or otherwise. Editors, however, do review author declarations, so specific relationships can be considered part of the review process.
AJSM authors are required to complete a declaration form that goes beyond the requirements of the International Committee of Medical Journal Editors. As each reader must act as the final evaluator and decide how much an article will influence his or her practice behavior, AJSM publishes this information near the beginning of every paper. Because we assume that a reader of the print edition is unlikely to run to a computer solely to access the authors' declaration, the complete information is included in both the print and electronic editions. The AJSM editorial team strives to minimize bias in the articles that appear on its pages; by emphasizing transparency in author declarations, our goal is to invite readers to share in the vetting process.
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